Abiraterone Acetate + Prednisone Cuts Metastasis in Prostate Cancer
And standard of care plus abiraterone improves survival in men with metastatic castration - sensitive prostate cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 27, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, Conference News, Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports 2021 First-Quarter Results
New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo a...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 ...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Yonsa (abiraterone acetate)
Title: Yonsa (abiraterone acetate)Category: MedicationsCreated: 10/2/2020 12:00:00 AMLast Editorial Review: 10/2/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 2, 2020 Category: Cancer & Oncology Source Type: news

Gut microbiome may influence how cancer patients respond to oral therapies, study suggests
(Lawson Health Research Institute) A new study from Lawson Health Research Institute and Western University illustrates how the gut microbiome interacts with an oral medication in prostate cancer patients, suggesting bacteria in the gut play a role in treatment outcomes. The findings, published in Nature Communications, highlight how the drug abiraterone acetate is metabolized by bacteria in the gut to reduce harmful organisms while promoting those that fight cancer. The team suspects this is one of many examples of how the microbiome influences our response to medications. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 29, 2020 Category: International Medicine & Public Health Source Type: news

Yonsa (Abiraterone Acetate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 18, 2020 Category: Drugs & Pharmacology Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

Breakthrough discovery to transform prostate cancer treatment
(University of South Australia) A novel formulation of the prostate cancer drug abiraterone acetate - currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials by the University of South Australia show the new formulation improves the drug's effectiveness by 40 per cent. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 20, 2020 Category: Biology Source Type: news

Dr Reddy's launches generic prostate cancer treatment drug in US
Pharma major Dr Reddy's Laboratories on Friday said it has launched generic Abiraterone Acetate tablets, used for treatment of prostate cancer, in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 18, 2020 Category: Pharmaceuticals Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Comorbid CVD May Up Mortality With ADT for Prostate Cancer
TUESDAY, Aug. 13, 2019 -- Elderly prostate cancer patients with preexisting cardiovascular diseases (CVDs) using abiraterone acetate (AA) or enzalutamide (ENZ) have higher short-term mortality compared with their counterparts without CVDs, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 13, 2019 Category: Pharmaceuticals Source Type: news

What Is the Ideal Glucocorticoid Regimen Combined With Abiraterone for Prostate Cancer?
Researchers compared several glucocorticoid regimens, given in combination with abiraterone acetate, for metastatic castration-resistant prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Final LATITUDE Results Confirm Previous Findings for High-Risk Prostate Cancer
Final results of LATITUDE confirm the beneft of abiraterone acetate plus prednisone along with ADT in high-risk metastatic castration-sensitive prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Abiraterone Risk Higher in Prostate Cancer Patients Who Have CVD Abiraterone Risk Higher in Prostate Cancer Patients Who Have CVD
A new analysis finds that men with prostate cancer treated with abiraterone acetate have a significantly higher mortality if they also have preexisting cardiovascular disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 6, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Zytiga May Up Mortality Risk in Prostate Cancer Patients With CVD
(MedPage Today) -- Increased hospitalizations seen among all abiraterone-treated patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 27, 2019 Category: Hematology Source Type: news

J & J Raises U.S. Prices on Around Two Dozen Drugs J & J Raises U.S. Prices on Around Two Dozen Drugs
Johnson& Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara (ustekinumab), prostate cancer drug Zytiga (abiraterone) and blood thinner Xarelto (rivaroxaban), all among its top-selling products.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

J & J raises U.S. drug prices
Johnson& Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 11, 2019 Category: Pharmaceuticals Source Type: news

J & amp;J raises U.S. drug prices
Johnson& Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 11, 2019 Category: Pharmaceuticals Source Type: news

J & J raises U.S. prices on around two dozen drugs
Johnson& Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among its top-selling products. (Source: Reuters: Health)
Source: Reuters: Health - January 10, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. appeals court declines J & J bid to stop generic Zytiga sales
A U.S. appeals court on Wednesday declined a request by Johnson& Johnson for an temporary restraining order blocking sales of generic versions of its cancer drug Zytiga from hitting the U.S. market. (Source: Reuters: Health)
Source: Reuters: Health - November 21, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Court Issues Ruling in ZYTIGA ® Patent Infringement Litigation
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 26, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson edges past profit estimates, lifts outlook
Johnson& Johnson reported slightly better-than-expected quarterly profit on Tuesday and pushed its full-year forecast higher, as demand for its cancer drugs Zytiga and Imbruvica helped offset falling sales of arthritis treatment Remicade. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson profit beats, lifts forecast on cancer drug demand
Johnson& Johnson on Tuesday reported quarterly profit above estimates and raised its full-year forecast, as demand for its cancer drugs Zytiga and Imbruvica helped offset decline in sales of blockbuster drug, Remicade. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson profit beat fueled by strength in pharma business
Johnson& Johnson topped analysts' estimates for quarterly profit and revenue on Tuesday, as strong demand for cancer drugs Zytiga and Darzalex more than made up for declining sales of blockbuster treatment Remicade. (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Yonsa (Abiraterone Acetate Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 7, 2018 Category: Drugs & Pharmacology Source Type: news

Sun Pharma Announces FDA Approval of Yonsa (abiraterone acetate) to Treat Metastatic Castration-Resistant Prostate Cancer
MUMBAI& PRINCETON, N.J.& KING OF PRUSSIA, Pa. May 23, 2018 --(BUSINESS WIRE)--Sun Pharmaceutical Industries Ltd. and includes its subsidiaries and/or associate companies) and Churchill Pharmaceuticals, LLC. (Churchill) today announced that... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 23, 2018 Category: Drugs & Pharmacology Source Type: news

Low-Dose Prostate Drug Can Match Standard Dose, Cut Costs Low-Dose Prostate Drug Can Match Standard Dose, Cut Costs
Patients who cannot afford to take abiraterone acetate for metastatic castration-resistant prostate cancer could benefit just as much from taking just a quarter dose with food, say US researchers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: Prostate cancer: How a full stomach could improve treatment
A new study finds that the prostate cancer drug Zytiga is more effective, as well as cheaper, when taken with food, as opposed to on an empty stomach. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 2, 2018 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

Full English could make prostate cancer treatment more effective
Current NHS guidelines for the drug abiraterone - also known as Zytiga - say it must be taken on an empty stomach. (Source: the Mail online | Health)
Source: the Mail online | Health - March 29, 2018 Category: Consumer Health News Source Type: news

Full English breakfast could make prostate cancer treatment more effective
Current NHS guidelines for the drug abiraterone - also known as Zytiga - say it must be taken on an empty stomach. (Source: the Mail online | Health)
Source: the Mail online | Health - March 29, 2018 Category: Consumer Health News Source Type: news

Low - Dose Abiraterone Acetate Noninferior for Prostate Cancer
Low - dose AA with low - fat breakfast had greater effect on PSA; similar effect to standard dose (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 29, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, Journal, Source Type: news

Low-Dose Abiraterone Acetate Noninferior for Prostate Cancer
WEDNESDAY, March 28, 2018 -- For castration-resistant prostate cancer (CRPC), low-dose abiraterone acetate (AA) with a low-fat breakfast is noninferior to standard dose with fasting in terms of the mean change in prostate-specific antigen (PSA),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2018 Category: Pharmaceuticals Source Type: news

A Light Breakfast Might Cut Cost of Pricey Prostate Cancer Drug, Zytiga (Abiraterone Acetate)
WEDNESDAY, March 28, 2018 -- Here's one way to cut the cost of a $10,000-a-month prostate cancer drug: Take it with food, some researchers suggest. Investigators said they found that taking Zytiga (abiraterone acetate) with a low-fat breakfast... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 28, 2018 Category: General Medicine Source Type: news

A Light Breakfast Might Cut Cost of Pricey Prostate Cancer Drug Zytiga
WEDNESDAY, March 28, 2018 -- Here's one way to cut the cost of a $10,000-a-month prostate cancer drug: Take it with food, some researchers suggest. Investigators said they found that taking Zytiga (abiraterone acetate) with a low-fat breakfast... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 28, 2018 Category: General Medicine Source Type: news

A Light Breakfast Might Cut Cost of Pricey Prostate Cancer Drug, #Zytiga (#Abiraterone Acetate)
WEDNESDAY, March 28, 2018 -- Here's one way to cut the cost of a $10,000-a-month prostate cancer drug: Take it with food, some researchers suggest. Investigators said they found that taking Zytiga (abiraterone acetate) with a low-fat breakfast... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 28, 2018 Category: General Medicine Source Type: news

Zytiga (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
HORSHAM, PA, Feburary 8, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga (abiraterone acetate) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 8, 2018 Category: Drugs & Pharmacology Source Type: news

ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
New indication for ZYTIGA® in combination with prednisone provides treatment option for patients with metastatic high-risk castration-sensitive prostate cancer Findings from pivotal Phase 3 LATITUDE clinical trial data demonstrated statistically sig... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, ZYTIGA, abiraterone, prostate cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 8, 2018 Category: Pharmaceuticals Source Type: news

ZYTIGA ® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

Janssen to Present 14 Abstracts in Prostate and Urothelial Cancers at ASCO GU 2018, Including New Data on Apalutamide (ARN-509), ZYTIGA ® (abiraterone acetate) and Erdafitinib
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 25, 2018 Category: Pharmaceuticals Source Type: news

U.S. Court Invalidates Patent on J & J Cancer Drug Zytiga U.S. Court Invalidates Patent on J & J Cancer Drug Zytiga
A U.S. administrative court on Wednesday invalidated a Johnson& Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 18, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

U.S. court invalidates J & J cancer drug patent, hitting UK's BTG
NEW YORK (Reuters) - A U.S. administrative court invalidated a Johnson& Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc . (Source: Reuters: Health)
Source: Reuters: Health - January 18, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson Issues Statement on ZYTIGA ® Inter Partes Reviews
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 18, 2018 Category: Pharmaceuticals Source Type: news

U.S. court invalidates patent on J & J cancer drug Zytiga
NEW YORK (Reuters) - A U.S. administrative court on Wednesday invalidated a Johnson& Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions. (Source: Reuters: Health)
Source: Reuters: Health - January 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Concern Over Adverse Events in Prostate Cancer Trial Concern Over Adverse Events in Prostate Cancer Trial
A phase 3 trial investigating the addition of radium-223 to abiraterone acetate plus steroid has been stopped after reports of fractures and deaths.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 1, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

30.11.17: Not intended for U.S. and UK Media
Phase III trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded earlyDecision follows a recommendation from an Independent Data Monitoring Committeemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 29, 2017 Category: Pharmaceuticals Source Type: news